AU2005238637B2 - Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination - Google Patents

Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination Download PDF

Info

Publication number
AU2005238637B2
AU2005238637B2 AU2005238637A AU2005238637A AU2005238637B2 AU 2005238637 B2 AU2005238637 B2 AU 2005238637B2 AU 2005238637 A AU2005238637 A AU 2005238637A AU 2005238637 A AU2005238637 A AU 2005238637A AU 2005238637 B2 AU2005238637 B2 AU 2005238637B2
Authority
AU
Australia
Prior art keywords
solution
ptx3
plates
well
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005238637A
Other languages
English (en)
Other versions
AU2005238637A1 (en
Inventor
Alberto Mantovani
Giuseppe Peri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LECTIO PHARMAENTWICKLUNGS-UND VERWERTUNGS GmbH
Original Assignee
LECTIO PHARMAENTWICKLUNGS und VERWERTUNGS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LECTIO PHARMAENTWICKLUNGS und VERWERTUNGS GmbH filed Critical LECTIO PHARMAENTWICKLUNGS und VERWERTUNGS GmbH
Publication of AU2005238637A1 publication Critical patent/AU2005238637A1/en
Application granted granted Critical
Publication of AU2005238637B2 publication Critical patent/AU2005238637B2/en
Assigned to LECTIO PHARMAENTWICKLUNGS-UND VERWERTUNGS GMBH reassignment LECTIO PHARMAENTWICKLUNGS-UND VERWERTUNGS GMBH Request for Assignment Assignors: FARMA DEVELOPMENT S.R.L.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2005238637A 2004-04-29 2005-04-27 Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination Ceased AU2005238637B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000858A ITMI20040858A1 (it) 2004-04-29 2004-04-29 Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione
ITMI2004A000858 2004-04-29
PCT/EP2005/004637 WO2005106494A2 (en) 2004-04-29 2005-04-27 Monoclonal antibodies, hybridomas, improved method for determining the protein ptx3 and kit for said determination

Publications (2)

Publication Number Publication Date
AU2005238637A1 AU2005238637A1 (en) 2005-11-10
AU2005238637B2 true AU2005238637B2 (en) 2010-12-16

Family

ID=35242298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005238637A Ceased AU2005238637B2 (en) 2004-04-29 2005-04-27 Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination

Country Status (9)

Country Link
US (1) US7915004B2 (enExample)
EP (1) EP1740956A2 (enExample)
JP (2) JP2007534951A (enExample)
KR (1) KR101168292B1 (enExample)
CN (1) CN1947018B (enExample)
AU (1) AU2005238637B2 (enExample)
CA (1) CA2562895A1 (enExample)
IT (1) ITMI20040858A1 (enExample)
WO (1) WO2005106494A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1947460B1 (en) * 2005-11-11 2012-05-30 The University of Tokyo Method of measuring ptx3 with high sensitivity
JP5199120B2 (ja) * 2005-12-29 2013-05-15 ヒューマニタス・ミラソーレ・エス．ピー．エー． 妊娠における炎症性内皮機能障害に対する診断試験
ATE475098T1 (de) * 2006-12-22 2010-08-15 Humanitas Mirasole Spa Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
WO2008099608A1 (ja) * 2007-02-15 2008-08-21 Saitama Medical University 炎症性腸疾患の診断方法
JP5832479B2 (ja) 2012-08-09 2015-12-16 日本特殊陶業株式会社 ガスセンサ
TWI528969B (zh) * 2013-06-07 2016-04-11 國立成功大學 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用
TWI741216B (zh) * 2017-09-19 2021-10-01 臻崴生物科技有限公司 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途
TWI754171B (zh) 2018-09-14 2022-02-01 臻崴生物科技有限公司 含單株抗體或其抗原結合片段之醫藥組成物及其用途
CN111024956A (zh) * 2019-12-31 2020-04-17 江苏美克医学技术有限公司 一种检测ptx3的时间分辨荧光免疫层析试剂盒
US20230251274A1 (en) * 2020-06-25 2023-08-10 Humanitas Mirasole S.P.A. Ptx3 as prognostic marker in covid-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05340945A (ja) * 1992-06-05 1993-12-24 Shiseido Co Ltd 微量物質測定方法及び測定キット
JPH0875737A (ja) * 1994-09-06 1996-03-22 Fuji Yakuhin Kogyo Kk ヒト前立腺特異抗原とヒトプロテインｃインヒビターとの複合体の測定方法および同測定用キット
JPH09220096A (ja) * 1996-02-16 1997-08-26 Meiji Milk Prod Co Ltd コレラトキシン及びその中和活性の新規 高感度測定法及び同キット
JP4427182B2 (ja) * 1997-09-22 2010-03-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原を安定化するための緩衝液
JP2002014098A (ja) * 2000-06-28 2002-01-18 Fujirebio Inc 免疫測定方法及びそのためのキット
ITRM20020109A1 (it) 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
US20040137544A1 (en) 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
JP4667372B2 (ja) * 2004-02-25 2011-04-13 株式会社ペルセウスプロテオミクス 血管障害の程度の判定方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fazzani, F. et al (2001) Arthritis & Rheumatism 44(12): 2841-2850 *
Muller, B. et al (2001) Critical Care Medicine 29(7): 1404-1407 *

Also Published As

Publication number Publication date
US20080261251A1 (en) 2008-10-23
JP2007534951A (ja) 2007-11-29
WO2005106494A3 (en) 2006-06-01
CN1947018A (zh) 2007-04-11
ITMI20040858A1 (it) 2004-07-29
JP2011117973A (ja) 2011-06-16
WO2005106494A2 (en) 2005-11-10
EP1740956A2 (en) 2007-01-10
AU2005238637A1 (en) 2005-11-10
KR20070006914A (ko) 2007-01-11
US7915004B2 (en) 2011-03-29
KR101168292B1 (ko) 2012-07-25
CN1947018B (zh) 2012-12-19
CA2562895A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
JP2011117973A (ja) タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット
Sudhakar et al. C-reactive protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor
Inadera The usefulness of circulating adipokine levels for the assessment of obesity-related health problems
Tan et al. Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis
Wehner et al. Utility of serum cystatin C as a clinical measure of renal function in dogs
Zhang et al. Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia
Coupes et al. TRANSFORMING GROWTH FACTOR β1 IN RENAL ALLOGRAFT RECIPIENTS1
US20060286681A1 (en) Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
Shokuhi et al. Levels of the chemokines growth‐related oncogene α and epithelial neutrophil‐activating protein 78 are raised in patients with severe acute pancreatitis
CN112526121A (zh) 血清淀粉样蛋白a检测试剂盒及其检测系统
US20160370365A1 (en) Method of evaluation of the relative risk of developing atherosclerosis in patients
Gombos et al. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure
US20130149712A1 (en) Follistatin-like protein-1 as a biomarker for inflammatory disorders
EP2092342B1 (en) A method for measuring plasma levels of pentraxin ptx3
Aref et al. Circulating vascular growth factor (VEGF) Angiopoietin-1 (Angi-1) and soluble Tie-2 receptor in pregnancy complicated with pre-eclampsia: a prospective study
US20120231477A1 (en) Blood Biomarkers for Bone Fracture and Cartilage Injury
Besbas et al. Monocyte chemoattractant protein-1 and interleukin-8 levels in children with acute poststreptococcal glomerulonephritis
Liu et al. Association of Soluble IL-1 Receptor Type 2 with Recovery of Left Ventricular Function and Clinical Outcomes in Acute Myocardial Infarction
US20060241036A1 (en) Soluble human interleukin 18 receptor-alpha, method of assaying the same, assay kit and medicinal composition
Connolly et al. Elevation of plasma fibronectin and serum amyloid P in autoimmune NZB, BW, and MRL1pr mice
Chougule et al. A multifaceted approach to lupus nephritis: Deciphering the interplay between adipokines, cytokines and complement proteins in disease pathogenesis
US20110104666A1 (en) Insulin resistance marker
WO2022221264A1 (en) Methods and compositions for analysis of acute kidney injury
BI-IL Human IL-6 ELISA
Yamada et al. Measurement of amyloidogenic SAA isotype, SAA1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LECTIO PHARMAENTWICKLUNGS-UND VERWERTUNGS GMBH

Free format text: FORMER OWNER WAS: FARMA DEVELOPMENT S.R.L.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired